Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS2 | P35228 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7617170 | 1.00 | NOS1 (0.47) | NOS1NOS2NOS3GGT1 | |
| Hydrochloric Acid SCHEMBL6130509 | 0.98 | NOS1 (0.49) | NOS1NOS2NOS3GGT1 | |
| Hydrochloric Acid SCHEMBL7605928 | 0.98 | NOS1 (0.49) | NOS1NOS2NOS3GGT1 | |
| Maleic Acid SCHEMBL27642880 | 0.94 | NOS1 (0.43) | NOS1NOS2NOS3 | |
| Maleic Acid SCHEMBL6267172 | 0.94 | NOS1 (0.43) | NOS1NOS2NOS3 | |
| Maleic Acid SCHEMBL2732805 | 0.93 | NOS1 (0.45) | NOS1NOS2NOS3 | |
| SCHEMBL7611659 | 0.85 | NOS1 (0.33) | NOS1NOS2NOS3 | |
| Salicylic Acid SCHEMBL6469549 | 0.83 | KDM4E (0.38) | NOS1NOS2NOS3 | |
| SCHEMBL6130546 | 0.82 | NOS1 (0.49) | NOS1NOS2NOS3 | |
| SCHEMBL6130684 | 0.81 | NOS3 (0.50) | NOS1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603870-A1 | S- 2- (1-IMINOETHYL)AMINO ETHYL -2-METHYL-L-C YSTEINE SALICYLATE MONOHYDRATE CRYSTALLINE SALT | Pharmacia Corporation (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1603671-A2 | METHODS FOR SELECTIVELY REMOVING COUNTERIONS FROM COMPOUNDS AND COMPOUNDS DERIVED FROM SUCH METHODS | Pharmacia Corporation (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1575563-A1 | NON-HYGROSCOPIC FORMULATION COMPRISING A HYDROSCOPIC DRUG | Pharmacia Corporation (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005025620-A2 | COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS | PHARMACIA CORPORATION (US) | 2005-03-24 | — | — | WO | claimed |
| WO-2004060353-A9 | SOLID DISPERSIONS COMPRISING A HYGROSCOPIC AND/OR DELIQUESCENT DRUG | PHARMACIA CORP (US) | 2004-10-07 | — | — | WO | claimed |
| WO-2004081073-A2 | METHODS FOR SELECTIVELY REMOVING COUNTERIONS FROM COMPOUNDS AND COMPOUNDS DERIVED FROM SUCH METHODS | PHARMACIA CORPORATION (US) | 2004-09-23 | — | — | WO | claimed |
| WO-2004080953-A1 | S-[2-[(1-IMINOETHYL)AMINO]ETHYL]-2-METHYL-L-CYSTEINE SALICYLATE MONOHYDRATE CRYSTALLINE SALT | PHARMACIA CORPORATION (US) | 2004-09-23 | — | — | WO | claimed |
| WO-2004060352-A1 | NON-HYGROSCOPIC FORMULATION COMPRISING A HYDROSCOPIC DRUG | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | claimed |
| EP-1265859-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | claimed |
| EP-1265860-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001072703-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | claimed |
| WO-2001072702-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | claimed |
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4346818-B1 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | VERTEX PHARMA (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-11-20 | — | — | US | disclosed |
| EP-1265859-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002076395-A2 | AGENTS AND METHODS FOR TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2001072703-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001072702-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN2B | NOS1 4023/4885NOS2 3313/4885NOS3 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.